Cell proliferation and cell cycle control: A mini review

International Journal of Clinical Practice

Volumn 58, Issue 12, 2004, Pages 1134-1141

  Golias, C H ^a   Charalabopoulos, A ^a   Charalabopoulos, K ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cell cycle; Cell cycle genes; Cell proliferation; Cyclin department kinases inhibitors; Cyclin dependent kinases; Cyclins

Indexed keywords

BROXURIDINE; CYCLIN A; CYCLIN B; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLINE; GROWTH FACTOR; HORMONE; I KAPPA B; IDOXURIDINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY KI 67; PROTEIN ANTIBODY; PROTEIN P53; RETINOBLASTOMA PROTEIN;

CANCER RISK; CARCINOGENESIS; CELL CYCLE; CELL CYCLE S PHASE; CELL FRACTIONATION; CELL GROWTH; CELL PROLIFERATION; COMPUTER PROGRAM; DNA DAMAGE; DNA SEQUENCE; ENZYME ACTIVITY; ESOPHAGUS CANCER; FLOW CYTOMETRY; GENE MUTATION; GENE TARGETING; HISTOGRAM; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG CANCER; MITOSIS INDEX; NONHUMAN; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; SHORT SURVEY; TUMOR GROWTH;

CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASES; CYCLINS; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MITOSIS; NEOPLASMS; PYRIMIDINES;

EID: 12344318996     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2004.00284.x     Document Type: Short Survey

References (54)

1. Malumbres M, Carnero A. Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res 2003; 5: 5-18.
2. Corn BG, El-Deiry WS. Derangement of growth and differentiation control in oncogenesis. Bioessays 2002; 24 (1): 83-90.
3. McDonald ER III, El-Deiry W. Checkpoint genes in cancer. Ann Med 2001; 33 (2): 113-22.
4. Gali-Muhtasib H, Bakkar N. Modulating cell cycle: current applications and prospects for future drug development. Curr Cancer Drug Targets 2002; 2 (4): 309-36.
5. Baserga R, Porcu P, Sell C. Oncogenes, growth factors and control of the cell cycle. Cancer Surv 1993; 16: 201-13.
6. Prober DA, Edgar BA. Growth regulation by oncogenes-new insights from model organisms. Curr Opin Genet Dev 2001; 11 (1): 19-26.
7. Lopez-Saez JF, de la Torre C, Pincheira J, Gimenez-Martin G. Cell proliferation and cancer. Histol Histopathol 1998; 13 (4): 1197-214.
8. el-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
9. Kastan M, Zhan Q, El-Diery W et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-98.
10. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391-9.
11. Fan R, Wu MT, Miller D et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9 (10): 1037-42.
12. cdc2 protein kinase. Biochem J 1992; 287: 965-9.
13. Bonneta L. Open questions on p16. Nature 1994; 370 180.
14. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato JY, Livingstone DM. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993; 73: 487-97.
15. Ferrel JJ, Wu M, Gerhart JC, Martin GS. Cell cycle tyrosine phosphorylation of p34cdc2 and a microtubule-associated protein kinase homolog in Xenopous oocytes and eggs. Mol Cell Biol 1991; 11: 1965-71.
16. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147 (3): 545-60.
17. Chan HM, Shikama N, La Thangue NB. Control of gene expression and the cell cycle. Essays Biochem 2001; 37: 87-96.
18. Harbour JW, Dean DC. Rb function in cell cycle regulation and apoptosis. Nat Cell Biol 2000; 2 (4): 65-7.
19. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of the retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992; 70: 993-1006.
20. Mittnacht S, Lees JA, Desai D, Harlow E, Morgan DO, Weinberg RA. Distinct subpopulations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J 1994; 13: 118-27.
21. 1-S phase protein-kinase. Science 1992; 257: 1958-61.
22. 1 phase of the human cell cycle. Science 1992; 157: 1689-94.
23. Herwig S, Strauss M. The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur J Biochem 1997; 246 (3): 581-601.
24. Claudio PP, Tonini T, Giordano A. The retinoblastoma family: twins or distant cousins? Genome Biol 2002; 3 (9): 3012.
25. Vernel R, Helin K, Muller H. Identification of target genes of the p16INK4A-pRB-E2F pathway. Biol Chem 2003; 278 (46): 124-37.
26. Yamasaki L. Role of the RB tumour suppressor in cancer. Cancer Treat Res 2003; 115: 209-39.
27. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-Kappa and cell cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001; 12 (1): 73-90.
28. Zhu MH, Ni CR, Zhu Z, Li FM, Zhang SM. Immunohistochemical demonstration of cyclins A,B,D1,D3 and E in hepatocellular carcinomas using tissue microarrays. Zhonghua Bing Li Xue Za Zhi 2003; 32 (5): 440-3.
29. Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 2002; 59 (8): 1317-26.
30. Zhou Q, He Q, Liang LJ. Expression of p27,cyclin E and cyclin A in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 2003; 9 (11): 2450-4.
31. Fong LY, Mancini R, Nakagawa H, Rustgi AK, Huebner K. Combined cyclin D1 overexpression and zinc deficiency disrupts cell cycle and accelerates mouse forestomach carcinogenesis. Cancer Res 2003; 63 (14): 4244-52.
32. Fischer H, Chen J, Skoog L, Lindoblom A. Cyclin D2 expression in familial and sporadic breast cancer. Oncol Rep 2002; 9 (6): 1157-61.
33. Lee MH, Yang HY. Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev 2003; 22 (4): 435-49.
34. Gutierrez C, Ramirez-Parra E, Castellano MM, del Pozo JC. G(1) to S phase transition: more than a cell cycle engine switch. Curr Opin Plant Biol 2002; 5 (6): 480-6.
35. Sedivy R, Thurner S, Budinsky AC, Kostler WJ, Zielinski CC. Short-term rhythmic proliferation of human breast cancer cell lines: surface effects and fractal growth patterns. J Pathol 2002; 197 (2): 163-9.
36. Watson JV. Tumour growth dynamics. Br Med Bull 1991; 47 (1): 47-63.
37. Rew DA, Wilson GD. Cell production rates in human tissues and tumours and their significance. Part 1: an introduction to the techniques of measurement and their limitations. Eur J Surg Oncol 2000; 26 (3): 227-38.
38. Rew DA, Wilson GD. Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur J Oncol 2000; 26 (4): 405-17.
39. Dubray B, Maciorowsky Z, Cosset JM, Terry NH. Clinical value of the potential doubling time (Tpot) measured by flow cytometry. Bull Cancer 1995; 82 (5): 331-8.
40. Bertuzzi A, Gandolfi A, Sinisgalli C, Starace G, Ubezio P. Cell loss and the concept of potential doubling time. Cytometry 1997; 29 (1): 34-40.
41. Schwindling SL, Faust M, Montenarh M. Determination of the mitotic index by microinjection of fluorescently labelled tubulin. Eur J Cell Biol 2002; 81 (3): 169-74.
42. Groenendijk RP, Bult P, Noppen CM, Boettes C, Ruers TJ, Wobbes T. Mitotic activity index in interval breast cancers. Eur J Surg Oncol 2003; 29 (1): 29-31.
43. Patel C, Sidhu KP, Shah MJ, Patel SM. Role of the mitotic counts in the grading and prognosis of the breast cancer. Indian J Pathol Microbiol 2002; 45 (3): 247-54.
44. Bergstrom C, Begg A, Palmqvist R, Waites A, Denekamp J. Labelling indices in human tumours: to apply or not - that is the question. Br J Cancer 1999; 80 (10): 1635-43.
45. Johansson MC, Johansson R, Baldetorp B, Oredsson SM. Comparison of different labelling index formulae used on bromodeoxyuridine-flow cytometry data. Cytometry 1998; 32 (3): 233-40.
46. Wilson GD, McNally NJ, Dische S et al. Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer 1988; 58 (4): 423-31.
47. Jourdan ML, Ferrero-Pous M, Spyratos F, Romain S, Martin PM, Chassevent A. Flow cytometric S - phase fraction measurement in breast carcinoma: Influence of software and histogram resolution. Cytometry 2002; 48 (2): 66-70.
48. Johnson HA. on the clinical significance of the S phase fractions of tumours. Ann Clin Lab Sci 1994; 24 (5): 431-5.
49. Wimberger P, Hillemanns P, Kapsner T, Hepp H, Kimming R. Evaluation of prognostic factors following flow-cytometric Dann analysis after cytokeratin labelling: I. Breast Cancer. Ann Cell Pathol 2002; 24 (4-5): 135-45.
50. Michels JJ, Duigou F, Marnay J, Denoux Y, Deloizier T, Chasle J. Flow cytometry in primary carcinomas. Prognostic impact of multiploidy and hypoploidy. Cytometry 2003; 55B (1): 37-45.
51. Chassevent A, Jourdan ML, Romain S et al. S-phase fraction and DNA ploidy in 633, T1T2 breast cancers. Clin Cancer Res 2001; 7: 909-17.
52. Nikolaeva TG, Dobrynin I, Letiagin VP, Prorokov V, Matiakin EG, Davydov MI. The experience in the use of DNA flow cytometry to predict the natural history of neoplasms. Vestn. Ross Akad Med Nauk 2002; 1: 45-9.
53. Turner HE, Wass JA. Are markers of proliferation valuable in the histological assessment of the pituitary tumours? Pituitary 1999; 1 (3-4): 147-51.
54. Martinez-Arribas F, Nunez MJ, Piqueras V et al. Flow cytometry vs Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases. Anticancer Res 2002; 22 (1A): 295-8.